Seres Therapeutics Inc Forecast, price target & analysts
Seres Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Seres Therapeutics Inc Classifications & Recommendation
Seres Therapeutics Inc Price Target
| Target Price | $17.34 |
| Price | $2.94 |
| Potential |
489.80%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Seres Therapeutics Inc 2027 .
The average Seres Therapeutics Inc target price is $17.34.
This is
489.80%
register free of charge
$23.10
685.71%
register free of charge
$12.12
312.24%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Seres Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Seres Therapeutics Inc stock has an average upside potential 2027 of
489.80%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.79 | 14.07 |
| 1,681.39% | ||
| EBITDA Margin | -11,372.15% | -540.69% |
| 95.25% | ||
| Net Margin | 721.52% | -250.43% |
| 134.71% |
4 Analysts have issued a sales forecast Seres Therapeutics Inc 2026 . The average Seres Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Seres Therapeutics Inc EBITDA forecast 2026. The average Seres Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Seres Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Seres Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.64 | -3.59 |
| 6,300.00% | 660.94% | |
| P/E | negative | |
| EV/Sales | 0.97 |
4 Analysts have issued a Seres Therapeutics Inc forecast for earnings per share. The average Seres Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Seres Therapeutics Inc...
Current Seres Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 23 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 13 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 24 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 23 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 13 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 24 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 14 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
